Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06858696 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
A Phase 1 study of Hepatic Insufficiency, sponsored by X4 Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06858696 is a Phase 1 study of Hepatic Insufficiency that is actively recruiting participants, run by X4 Pharmaceuticals. The registered enrollment target is 48 participants, above the 36-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (33% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT06858696, a Phase 1 study of Hepatic Insufficiency, is actively recruiting participants, sponsored by X4 Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
Conditions Studied
Interventions
- DRUG Mavorixafor
Study Locations (4)
California
- Catalina Research Institute, LLC - Montclair
- Catalina Research Institute, LLC - Rialto
Florida
- Orlando Clinical Research Center - Orlando
Texas
- Texas Liver Institute/Alamo Medical Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06858696
The ClinicalTrials.gov registry entry for NCT06858696 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 36-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (33% higher). The listed sponsor is X4 Pharmaceuticals, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which Mavorixafor is the first listed.
NCT06858696 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06858696 about?
NCT06858696 is a clinical study titled "A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function". The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
What is the current status of trial NCT06858696?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-02-28. Estimated completion is 2026-04.
What conditions does trial NCT06858696 study?
This clinical trial studies the following conditions: Hepatic Insufficiency.
What interventions are being tested in trial NCT06858696?
The interventions under investigation include: Mavorixafor (DRUG).
Who is sponsoring clinical trial NCT06858696?
This trial is sponsored by X4 Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06858696 being conducted?
This trial has 4 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RECRUITING · Phase 1
-
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
COMPLETED · Phase 1
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
COMPLETED · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
COMPLETED · Phase 1
-
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.